“Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data”, J of Skin, vol. 2, p. S78, Dec. 2018, doi: 10.25251/skin.2.supp.78.